Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Clinical pharmacogenomics - aims and importance
- Genetic variability of drug response
- Genetic polymorphisms in drug metabolism
- Influence of polymorphisms in DME
- Practical consequence of genetic variability
- Genetic-based dose adjustments: an example
- Future use of pharmacogenetic diagnostics
- Polymorphic drug metabolizing enzymes
- Cytochrome P450 enzyme 2D6
- Variable doxepin kinetics dependent on CYP2D6
- CYP2D6 genotype based dose adjustment
- CYP2D6 in mirtazapine kinetics
- Role of CYP2D6 in antidepressant drug treatment
- CYP2D6 physiological role
- Serotonin in platelets after 75 mg doxepin
- CYP2D6 varients affect antidepressant treatment
- CYP2D6-based dose adjustments - summary
- Several polymorphic CYP affect one drug
- Frequency of mixed CYP genotypes
- Choosing study volunteers according to genotypes
- Trimipramine and different CYP genotypes
- Dose adjustments according to CYP2C219
- Genotype based dose adjustments - limitations
- Genotype-phenotype interactions
- CYP2D6 inter-ethnic differences
- Clinical validations of dosage adjustments
- Pharmacogenetics of mood stabilizers
- Lithium
- Carbamazepine
- Types of adverse drug reactions
- Adverse reactions in antidepressants
- CYP2D6 genotype in depressed patients with ADR
- Adverse effects of antipsychotics
- CYP2D6 and haloperidol clearance
- Extrapyramidal symptoms and CYP2D6
- CYP2D6 and tolerability of risperidone
- Summary
- Acknowledgements
Topics Covered
- Factors that determine psychiatric importance of genetic variants
- Consequences which arise from genotyping
- Drugs are metabolized via the polymorphic cytochrome P450 enzyme CYP2D6
- Differences in pharmacokinetic parameters for tricyclics, some SSRIs, other antidepressants, typical and some atypical antipsychotic drugs
- Effects on therapeutic efficacy and adverse events
- Indication for genotyping in psychotropic drug treatment
- Future research to close the gap between pharmacogenetic research and clinical practice
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stingl (formerly Kirchheiner), J. (2007, October 1). Genetic determinants of metabolism: clinical applications in psychiatry [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/OHAM8221.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Julia Stingl (formerly Kirchheiner) has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Genetic determinants of metabolism: clinical applications in psychiatry
A selection of talks on Neurology
Hide